{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:44:01Z","timestamp":1792147441457,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010438","name":"Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu","doi-asserted-by":"publisher","award":["NMN0000171"],"award-info":[{"award-number":["NMN0000171"]}],"id":[{"id":"10.13039\/501100010438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12012-026-10191-y","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:10:02Z","timestamp":1789902602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4760-2618","authenticated-orcid":false,"given":"Paulina","family":"Szubi\u0144ska-Ba\u0142aban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1063-8318","authenticated-orcid":false,"given":"Aneta","family":"Klotzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9933-2395","authenticated-orcid":false,"given":"Katarzyna","family":"Zi\u00f3\u0142kowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0967-009X","authenticated-orcid":false,"given":"Patrycja","family":"Marciniak-St\u0119pak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0833-6759","authenticated-orcid":false,"given":"Julia","family":"Niedzielska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8457-7822","authenticated-orcid":false,"given":"Federico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-2717","authenticated-orcid":false,"given":"Amro Abu","family":"Suleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4456-6095","authenticated-orcid":false,"given":"Filip","family":"Glista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7860-8176","authenticated-orcid":false,"given":"Angelika","family":"Kuczmarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0509-1696","authenticated-orcid":false,"given":"Ewelina","family":"Bukowska-Olech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"10191_CR1","volume":"76","author":"H Sung","year":"2026","unstructured":"Sung, H., et al. (2026). Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: A Cancer Journal for Clinicians, 76, Article e70090.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10191_CR2","volume":"13","author":"HS Ng","year":"2024","unstructured":"Ng, H. S., et al. (2024). Cardiovascular mortality in people with cancer compared to the general population: A systematic review and meta-analysis. Cancer Medicine, 13, Article e70057.","journal-title":"Cancer Medicine"},{"key":"10191_CR3","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon, A. R. (2022). ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS. European Heart Journal, 43, 4229\u20134361.","journal-title":"European Heart Journal"},{"key":"10191_CR4","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","volume":"44","author":"LP Grazette","year":"2004","unstructured":"Grazette, L. P. (2004). Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes. Journal Of The American College Of Cardiology, 44, 2231\u20132238.","journal-title":"Journal of the American College of Cardiology"},{"key":"10191_CR5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphys.2018.00167","volume":"9","author":"G Varricchi","year":"2018","unstructured":"Varricchi, G. (2018). Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Frontiers In Physiology, 9, 167.","journal-title":"Frontiers in Physiology"},{"issue":"Suppl 1","key":"10191_CR6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2459\/JCM.0000000000000373","volume":"17","author":"M Deidda","year":"2016","unstructured":"Deidda, M. (2016). Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection. Journal of Cardiovascular Medicine Hagerstown, 17(Suppl 1), 76\u201383.","journal-title":"Journal of Cardiovascular Medicine Hagerstown"},{"key":"10191_CR7","volume":"9","author":"TK Al-Otaibi","year":"2022","unstructured":"Al-Otaibi, T. K., Weitzman, B., Tahir, U. A., & Asnani, A. (2022). Genetics of anthracycline-associated cardiotoxicity. Frontiers in Cardiovascular Medicine, 9, Article 867873.","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10191_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.117.001753","author":"M Linschoten","year":"2018","unstructured":"Linschoten, M., Teske, A. J., Cramer, M. J., Wall, E., & Asselbergs, F. W. (2018). Chemotherapy-related cardiac dysfunction: A systematic review of genetic variants modulating individual risk. Circulation. Genomic and Precision Medicine. https:\/\/doi.org\/10.1161\/CIRCGEN.117.001753","journal-title":"Circulation. Genomic and Precision Medicine"},{"key":"10191_CR9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1634\/theoncologist.2019-0762","volume":"25","author":"I Raber","year":"2020","unstructured":"Raber, I. (2020). Fluoropyrimidine-associated cardiotoxicity: A retrospective case-control study. The Oncologist, 25, 606\u2013609.","journal-title":"The Oncologist"},{"key":"10191_CR10","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. (2016). Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal Of Medicine, 375, 1749\u20131755.","journal-title":"New England Journal Of Medicine"},{"key":"10191_CR11","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E. (2018). Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. The Lancet Oncology, 19, 1579\u20131589.","journal-title":"The Lancet Oncology"},{"key":"10191_CR12","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","volume":"47","author":"JR Power","year":"2026","unstructured":"Power, J. R. (2026). Immune checkpoint inhibitor-associated myocarditis: A novel risk score. European Heart Journal, 47, 1050\u20131062.","journal-title":"European Heart Journal"},{"key":"10191_CR13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021686","volume":"10","author":"E Belzile-Dugas","year":"2021","unstructured":"Belzile-Dugas, E., & Eisenberg, M. J. (2021). Radiation-induced cardiovascular disease: Review of an underrecognized pathology. Journal of the American Heart Association, 10, Article 021686.","journal-title":"Journal of the American Heart Association"},{"key":"10191_CR14","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale, D., et al. (2015). Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation, 131, 1981\u20131988.","journal-title":"Circulation"},{"key":"10191_CR15","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang, S. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Medicine, 18, 1639\u20131642.","journal-title":"Nature Medicine"},{"key":"10191_CR16","doi-asserted-by":"crossref","first-page":"e0158376","DOI":"10.1371\/journal.pone.0158376","volume":"11","author":"B Aryal","year":"2016","unstructured":"Aryal, B., & Rao, V. A. (2016). Deficiency in Cardiolipin Reduces Doxorubicin-Induced Oxidative Stress and Mitochondrial Damage in Human B-Lymphocytes. PLOS ONE, 11, e0158376.","journal-title":"PLOS ONE"},{"key":"10191_CR17","doi-asserted-by":"crossref","first-page":"132747","DOI":"10.1172\/jci.insight.132747","volume":"5","author":"T Tadokoro","year":"2020","unstructured":"Tadokoro, T. (2020). Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight, 5, 132747.","journal-title":"JCI Insight"},{"key":"10191_CR18","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1073\/pnas.1821022116","volume":"116","author":"X Fang","year":"2019","unstructured":"Fang, X. (2019). Ferroptosis as a target for protection against cardiomyopathy. Proceedings Of National Academy Of Sciences, 116, 2672\u20132680.","journal-title":"Proceedings of National Academy of Sciences"},{"key":"10191_CR19","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1038\/onc.2011.130","volume":"30","author":"BN Rexer","year":"2011","unstructured":"Rexer, B. N. (2011). Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene, 30, 4163\u20134174.","journal-title":"Oncogene"},{"key":"10191_CR20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.freeradbiomed.2023.06.019","volume":"206","author":"T Ye","year":"2023","unstructured":"Ye, T. (2023). Trastuzumab-induced cardiomyopathy via ferroptosis-mediated mitochondrial dysfunction. Free Radical Biology And Medicine, 206, 143\u2013161.","journal-title":"Free Radical Biology and Medicine"},{"key":"10191_CR21","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu, T. F. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet, 370, 2011\u20132019.","journal-title":"The Lancet"},{"key":"10191_CR22","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes, J. E. (2013). A Phase 2 Trial of Ponatinib in Philadelphia Chromosome\u2013Positive Leukemias. New England Journal Of Medicine, 369, 1783\u20131796.","journal-title":"New England Journal of Medicine"},{"key":"10191_CR23","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkel\u00e4","year":"2006","unstructured":"Kerkel\u00e4, R. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12, 908\u2013916.","journal-title":"Nature Medicine"},{"key":"10191_CR24","first-page":"117","volume":"15","author":"SG Arbuck","year":"1993","unstructured":"Arbuck, S. G. (1993). A reassessment of cardiac toxicity associated with Taxol. Journal of the National Cancer Institute Monographs, 15, 117\u2013130.","journal-title":"Journal of the National Cancer Institute Monographs"},{"key":"10191_CR25","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3892\/etm.2021.10886","volume":"22","author":"Y Li","year":"2021","unstructured":"Li, Y. (2021). Dynamic observation of 5-fluorouracil\u2010induced myocardial injury and mitochondrial autophagy in aging rats. Exp Ther Med, 22, 1451.","journal-title":"Exp Ther Med"},{"key":"10191_CR26","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni, Z. D. (2020). Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation, 142, 2299\u20132311.","journal-title":"Circulation"},{"key":"10191_CR27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28162","author":"KS Hanna","year":"2022","unstructured":"Hanna, K. S. (2022). Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review. Cureus. https:\/\/doi.org\/10.7759\/cureus.28162. https:\/\/doi","journal-title":"Cureus"},{"key":"10191_CR28","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.medj.2025.100800","volume":"6","author":"S Kungwankiattichai","year":"2025","unstructured":"Kungwankiattichai, S., Desai, A., Koppinger, S., & Maziarz, R. T. (2025). Immune-related adverse events associated with cancer immunotherapy. Med, 6, 100800.","journal-title":"Med"},{"key":"10191_CR29","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s11864-023-01130-y","volume":"24","author":"M Patel","year":"2023","unstructured":"Patel, M. (2023). Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond. Current Treatment Options In Oncology, 24, 1489\u20131503.","journal-title":"Current Treatment Options in Oncology"},{"key":"10191_CR30","doi-asserted-by":"crossref","first-page":"102383","DOI":"10.1016\/j.esmoop.2024.102383","volume":"9","author":"JSW Borgers","year":"2024","unstructured":"Borgers, J. S. W. (2024). Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: Diagnostic challenges and lessons learned. ESMO Open, 9, 102383.","journal-title":"ESMO Open"},{"key":"10191_CR31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-16-0908","volume":"23","author":"BP Schneider","year":"2017","unstructured":"Schneider, B. P. (2017). Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clinical Cancer Research, 23, 43\u201351.","journal-title":"Clinical Cancer Research"},{"key":"10191_CR32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.121.055801","volume":"145","author":"T Magdy","year":"2022","unstructured":"Magdy, T. (2022). Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. Circulation, 145, 279\u2013294.","journal-title":"Circulation"},{"key":"10191_CR33","first-page":"26","volume":"10","author":"HM Boen","year":"2024","unstructured":"Boen, H. M. (2024). Variants in structural cardiac genes in patients with cancer therapy-related cardiac dysfunction after anthracycline chemotherapy: A case-control study. Cardio-Oncol, 10, 26.","journal-title":"Cardio-Oncol"},{"key":"10191_CR34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","volume":"140","author":"P Garcia-Pavia","year":"2019","unstructured":"Garcia-Pavia, P. (2019). Genetic Variants Associated With Cancer Therapy\u2013Induced Cardiomyopathy. Circulation, 140, 31\u201341.","journal-title":"Circulation"},{"key":"10191_CR35","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ng.3374","volume":"47","author":"F Aminkeng","year":"2015","unstructured":"Aminkeng, F. (2015). A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature Genetics, 47, 1079\u20131084.","journal-title":"Nature Genetics"},{"key":"10191_CR36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2015.63.4550","volume":"34","author":"X Wang","year":"2016","unstructured":"Wang, X. (2016). CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children\u2019s Oncology Group Genome-Wide Association Study. Journal Of Clinical Oncology, 34, 863\u2013870.","journal-title":"Journal of Clinical Oncology"},{"key":"10191_CR37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.2013.50.3557","volume":"32","author":"X Wang","year":"2014","unstructured":"Wang, X. (2014). Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children\u2019s Oncology Group. Journal Of Clinical Oncology, 32, 647\u2013653.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10191_CR38","doi-asserted-by":"publisher","first-page":"7171","DOI":"10.1038\/s41467-022-34917-y","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu, X. (2022). A non-coding GWAS variant impacts anthracycline-induced cardiotoxic phenotypes in human iPSC-derived cardiomyocytes. Nature Communications, 13, 7171.","journal-title":"Nature Communications"},{"key":"10191_CR39","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.stem.2021.08.006","volume":"28","author":"T Magdy","year":"2021","unstructured":"Magdy, T. (2021). RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell Stem Cell, 28, 2076\u201320897.","journal-title":"Cell Stem Cell"},{"key":"10191_CR40","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","volume":"30","author":"H Visscher","year":"2012","unstructured":"Visscher, H. (2012). Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. Journal Of Clinical Oncology, 30, 1422\u20131428.","journal-title":"Journal of Clinical Oncology"},{"key":"10191_CR41","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1186\/s12885-018-4629-6","volume":"18","author":"JC S\u00e1gi","year":"2018","unstructured":"S\u00e1gi, J. C. (2018). Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. Bmc Cancer, 18, 704.","journal-title":"BMC Cancer"},{"key":"10191_CR42","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/annonc\/mdm181","volume":"18","author":"S Beauclair","year":"2007","unstructured":"Beauclair, S. (2007). Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Annals Of Oncology, 18, 1335\u20131341.","journal-title":"Annals of Oncology"},{"key":"10191_CR43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12885-015-1298-6","volume":"15","author":"SE Stanton","year":"2015","unstructured":"Stanton, S. E. (2015). Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. Bmc Cancer, 15, 267.","journal-title":"BMC Cancer"},{"key":"10191_CR44","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout, A. H. (2016). Angiotensin II\u2013receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: A randomized clinical trial. JAMA Oncology, 2, 1030.","journal-title":"JAMA Oncology"},{"key":"10191_CR45","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1248\/bpb.b19-00527","volume":"42","author":"MH Nakano","year":"2019","unstructured":"Nakano, M. H. (2019). A genome-wide association study identifies five novel genetic markers for trastuzumab-induced cardiotoxicity in Japanese population. Biological & Pharmaceutical Bulletin, 42, 2045\u20132053.","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10191_CR46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17213443","volume":"17","author":"L Tarantini","year":"2025","unstructured":"Tarantini, L. (2025). A new era, new risks: The cardio-oncology perspective on immunotherapy in non-small cell lung cancer. Cancers, 17, Article 3443.","journal-title":"Cancers"},{"key":"10191_CR47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/hmg\/ddaa137","volume":"29","author":"JA Castrillon","year":"2020","unstructured":"Castrillon, J. A., Eng, C., & Cheng, F. (2020). Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. Human Molecular Genetics, 29, 186\u2013196.","journal-title":"Human Molecular Genetics"},{"key":"10191_CR48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1158105","volume":"14","author":"Y Gonzalez-Montes","year":"2023","unstructured":"Gonzalez-Montes, Y. (2023). Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma. Frontiers in Immunology, 14, Article 1158105.","journal-title":"Frontiers in Immunology"},{"key":"10191_CR49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/eurheartj\/ehae496","volume":"46","author":"B Rivero-Santana","year":"2025","unstructured":"Rivero-Santana, B. (2025). Anthracycline-induced cardiovascular toxicity: Validation of the Heart Failure Association and International Cardio-Oncology Society risk score. European Heart Journal, 46, 273\u2013284.","journal-title":"European Heart Journal"},{"key":"10191_CR50","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/ejhf.3753","volume":"27","author":"A Rakisheva","year":"2025","unstructured":"Rakisheva, A. (2025). Prevention of Cancer Therapy-Related Cardiac Dysfunction and Heart Failure in Cancer Patients and Survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology. European Journal Of Heart Failure, 27, 2084\u20132099.","journal-title":"European Journal of Heart Failure"},{"key":"10191_CR51","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-084062","volume":"390","author":"C Gomes","year":"2025","unstructured":"Gomes, C. (2025). Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: Systematic review and meta-analysis. BMJ, 390, Article 084062.","journal-title":"BMJ"},{"key":"10191_CR52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612694","volume":"24","author":"R Abbas Syed","year":"2023","unstructured":"Abbas Syed, R., Davey, M. G., Richard, V., Miller, N., & Kerin, M. J. (2023). Biological implications of microRNAs as regulators and biomarkers of therapeutic toxicities in breast cancer. International Journal of Molecular Sciences, 24, Article 12694.","journal-title":"International Journal of Molecular Sciences"},{"key":"10191_CR53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.316061","author":"D Han","year":"2020","unstructured":"Han, D. (2020). The tumor-suppressive human circular RNA CircITCH sponges miR-330-5p to ameliorate doxorubicin-induced cardiotoxicity through upregulating SIRT6, survivin, and SERCA2a. Circulation Research. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.316061","journal-title":"Circulation Research"},{"key":"10191_CR54","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1159\/000447853","volume":"39","author":"M Su","year":"2016","unstructured":"Su, M. (2016). Cardiac-Specific Overexpression of miR-222 Induces Heart Failure and Inhibits Autophagy in Mice. Cellular Physiology And Biochemistry, 39, 1503\u20131511.","journal-title":"Cellular Physiology and Biochemistry"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10191-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10191-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10191-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:46:30Z","timestamp":1792143990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10191-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10191"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10191-y","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"assertion":[{"value":"17 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"113"}}